[EVOK] Evoke Pharma, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2 Change: -0.02 (-0.99%)

chart EVOK

Refresh chart

Strongest Trends Summary For EVOK

EVOK is in the medium-term up 16% above S&P in 3 months.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on developing drugs for the treatment of gastroenterological disorders and diseases. It is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded in 2007 and is headquartered in Solana Beach, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-109.45% ROE-214.72% ROI
Current Ratio5.03 Quick Ratio Long Term Debt/Equity Debt Ratio0.39
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities530 K Cash From Investing Activities Cash From Operating Activities-3 M Gross Profit
Net Profit-3.52 M Operating Profit-3.45 M Total Assets12.62 M Total Current Assets12.57 M
Total Current Liabilities2.5 M Total Debt4.4 M Total Liabilities6.19 M Total Revenue
Technical Data
High 52 week3.33 Low 52 week1.9 Last close3.1 Last change-0.32%
RSI61.97 Average true range0.11 Beta0.93 Volume399.59 K
Simple moving average 20 days4.53% Simple moving average 50 days14.32% Simple moving average 200 days13.86%
Performance Data
Performance Week1.97% Performance Month9.54% Performance Quart28.1% Performance Half23.51%
Performance Year53.47% Performance Year-to-date25% Volatility daily2.04% Volatility weekly4.56%
Volatility monthly9.34% Volatility yearly32.34% Relative Volume136.77% Average Volume36.84 K
New High New Low

News

2019-03-14 08:30:00 | Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA

2019-03-06 08:30:00 | Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication

2019-03-04 08:30:00 | Evoke Pharma Receives Preliminary FDA Communication on Gimoti™ NDA

2019-02-27 08:30:00 | Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

2019-01-07 08:30:00 | Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners

2019-01-04 07:56:38 | Loss-Making Evoke Pharma, Inc. NASDAQ:EVOK Expected To Breakeven

2018-11-13 16:05:00 | Evoke Pharma Reports Third Quarter 2018 Results

2018-10-16 10:32:52 | Shareholders Should Check The Ownership Structure Of Evoke Pharma Inc NASDAQ:EVOK

2018-10-08 18:28:10 | Generic-Drugs Stock Outlook: No Respite from Pricing Issues

2018-09-28 09:59:01 | Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead

2018-08-17 09:12:01 | Evoke Pharma EVOK Announces FDA Acceptance of Gimoti NDA

2018-08-16 08:30:00 | Evoke Pharma’s Gimoti™ NDA Accepted for FDA Review

2018-08-09 16:05:00 | Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights

2018-06-06 13:38:23 | At $2.8701, Is Evoke Pharma Inc NASDAQ:EVOK A Buy?

2018-06-04 07:30:00 | Evoke Announces FDA Submission of New Drug Application for Gimoti™

2018-05-14 10:27:15 | Evoke Pharma Inc NASDAQ:EVOK Is Expected To Breakeven

2018-05-14 06:30:00 | Evoke Pharma Reports First Quarter 2018 Results and Highlights

2018-05-10 07:30:00 | Evoke Granted Gender Specific Patent for Gimoti™ in Mexico

2018-04-30 07:30:00 | Evoke Granted First Gender Specific Patent for Gimoti™

2018-03-26 07:30:00 | Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments

2018-03-07 16:05:00 | Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights

2018-03-07 12:00:00 | Evoke Pharma, Inc. to Host Earnings Call

2018-03-06 07:30:00 | Evoke Pharma to Present at the Upcoming Roth and Oppenheimer Investor Conferences

2018-03-05 07:30:00 | FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application

2018-02-21 08:30:00 | Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results

2018-02-15 07:30:00 | Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™

2017-12-12 07:40:00 | Wired News – Akari’s Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary Endpoint

2017-12-11 07:30:00 | Wired News – SteadyMed Reported FDA Agreed Pathway to Trevyent NDA Resubmission

2017-11-14 16:05:00 | Evoke Pharma Reports Third Quarter 2017 Results and Highlights

2017-11-14 12:00:00 | Evoke Pharma, Inc. to Host Earnings Call

2017-11-14 06:49:08 | A Look At Evoke Pharma Inc EVOK And The Healthcare Sector

2017-11-09 08:30:00 | Evoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific

2017-11-07 08:30:00 | Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results

2017-11-07 06:33:29 | Is It The Right Time To Buy Evoke Pharma Inc EVOK?

2017-10-27 08:30:00 | Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti™

2017-10-23 07:30:00 | Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti™

2017-10-17 09:53:01 | New Strong Sell Stocks for October 17th

2017-10-04 08:30:00 | Evoke Pharma to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference

2017-09-12 08:30:00 | Evoke Pharma Completes Dosing for Gimoti™ Comparative Exposure Pharmacokinetic Study

2017-09-05 08:30:00 | Evoke Pharma to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

2017-08-14 16:05:00 | Evoke Pharma Reports Second Quarter 2017 Results and Highlights

2017-08-14 12:10:00 | Investor Network: Evoke Pharma, Inc. to Host Earnings Call

2017-08-14 08:30:00 | Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti™

2017-08-07 08:30:00 | Evoke Pharma Schedules Conference Call and Webcast for Second Quarter 2017 Financial Results

2017-05-31 08:30:00 | Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti

2017-05-15 16:05:00 | Evoke Pharma Reports First Quarter 2017 Results

2017-05-15 15:00:00 | Investor Network: Evoke Pharma, Inc. to Host Earnings Call

2017-05-10 08:30:00 | Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017

2017-05-01 08:30:00 | Evoke Pharma Schedules Conference Call and Webcast for First Quarter 2017 Financial Results

2017-04-18 08:30:00 | Evoke Pharma Announces Collaboration with Spaulding Clinical Research for the Gimoti Comparative Exposure Pharmacokinetic Trial